

**BLUE CROSS** 

An Independent Licensee of the Blue Cross Blue Shield Associatio

# MEDICAL POLICY – 2.01.534 Intra-Articular Hyaluronan Injections for Osteoarthritis

BCBSA Ref. Policy	r: 2.01.31	
Effective Date:	Jul. 1, 2025	RELATED MEDICAL POLICIES:
Last Revised:	Jun. 23, 2025	1.01.27 Electrical and Electromagnetic Stimulation for the Treatment of Arthritis
Replaces:	N/A	2.01.535 Temporomandiular Joint Disorder

## Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

### Introduction

Hyaluronan, or sodium hyaluronate, is a natural substance found in some joints of the human body. This substance acts as a lubricant to help the joints work better. There are also other substances similar to hyaluronan that have been used for the past several years to try to treat knee pain due to osteoarthritis of the knee. These substances have been manufactured to be injected into the knee one or more times. Early studies suggested the injections helped decrease pain. However, during the past 5 years, re-analysis of the best early medical studies that included thousands of individuals have shown that these injections do not offer significant relief for most people. Some professional societies recommend that these injections not be used. Based on the changing scientific evidence, the plan considers hyaluronan injections in the knee not medically necessary. Use of these injections in all other joints is considered investigational (unproven) because there are so few studies published about other joints. The plan does not pay for services that are not medically necessary or investigational.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

# Policy Coverage Criteria

Procedure	Medical Necessity
Intra-articular hyaluronan	Intra-articular hyaluronan injections of the knee are
injections of the knee	considered not medically necessary.

Procedure	Investigational
Intra-articular hyaluronan	Intra-articular hyaluronan injections are considered
injections, all other joints	investigational for all other joints.

# Coding

Code	Description
HCPCS	
J7318	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg
J7320	Hyaluronan or derivitive, Genvisc 850, for intra-articular injection, 1 mg
J7321	Hyaluronan or derivative, Hyalgan Supartz, or Visco-3, for intra-articular injection, per dose
J7322	Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose
J7328	Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg
J7329	Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg
J7331	Hyaluronan or derivative, SYNOJOYNT, for intra-articular injection, 1 mg
J7332	Hyaluronan or derivative, Triluron, for intra-articular injection, 1 mg

**Note:** CPT codes, descriptions, and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

### **Related Information**

N/A

### **Evidence Review**

### Description

Intra-articular (IA) injection of hyaluronan into osteoarthritic joints is proposed to reduce pain and improve function. It is thought to replace endogenous hyaluronan and restore the viscoelastic properties of the synovial fluid. Most studies to date have assessed hyaluronan injections for knee osteoarthritis (OA), the US Food and Drug Administration (FDA) approved indication. Other joints (e.g., hip, shoulder) are being investigated for IA hyaluronan treatment of OA.

### Background

### **Knee Osteoarthritis**

Knee OA is common, costly, and a cause of substantial disability. Among US adults, the most common causes of disability are arthritis and rheumatic disorders.

### Treatment

Currently, no curative therapy is available for OA, and thus the overall goals of management are to reduce pain, disability, and the need for surgery.

IA injection of hyaluronan has been proposed as a means of restoring the normal viscoelasticity of the synovial fluid in individuals with OA and reducing pain and improving function. This



treatment may also be called viscosupplementation. Hyaluronan is a naturally occurring macromolecule that is a major component of synovial fluid and is thought to contribute to its viscoelastic properties. Chemical crosslinking of hyaluronan increases its molecular weight; cross-linked hyaluronans are referred to as hylans. In OA, the overall length of hyaluronan chains present in cartilage and the hyaluronan concentration in the synovial fluid are decreased.

### **Summary of Evidence**

For individuals who have OA of the knee who receive IA hyaluronan injections, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. The relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. Many RCTs have been published over the last 2 decades. While outcomes of these RCTs are mixed, the RCT evidence base is characterized by studies showing small treatment effects of IA hyaluronan injections. In many cases, these trials are at risk of bias, and it cannot be determined with certainty whether there is a true treatment effect or whether the reported differences are due to bias. Meta-analyses of RCTs have also had mixed findings. Some meta-analyses, estimating the magnitude of treatment benefit, have concluded that there is no clinically significant benefit; others have concluded that there is a clinically significant benefit. These meta-analyses have also highlighted the limitations of this evidence base, most notably publication bias and small trial bias. For example, a meta-analysis (2016) found more than a 3-fold larger treatment effect in small trials than in larger trials (i.e., more than 100 participants). Overall, given the lack of a definitive treatment benefit despite a large quantity of literature, and given the biases present in the available evidence, it is unlikely that there is a treatment benefit that is clinically meaningful. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have OA of joints other than the knee who receive IA hyaluronan injections, the evidence includes RCTs, systematic reviews of RCTs, and observational studies. The relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. Meta-analyses of RCTs either have not found statistically significant benefits of the procedure on health outcomes or have found benefits that were statistically, but likely not clinically, significant (e.g., 0.27-point improvement on a 10-point visual analog scale for hip OA). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

# **Ongoing and Unpublished Clinical Trials**

Some currently ongoing and unpublished trials that might influence this review are listed in **Table 1**.

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT06279507	The Efficacy of Hyaluronic Acid Injection as an Adjunctive Treatment After Intraarticular Low-dose Glucocorticoid Injection for Symptomatic Knee Osteoarthritis: A Multicenter Randomized, Controlled, Double-blinded Study	176	Jun 2025
Unpublished			
NCT04231318	A Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee	231	May 2022
NCT06043544	Hymovis Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis: a Monocentric Randomized Open-label Trial	80	Mar 2022
NCT04204265ª	A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint	25	Mar 2021 (completed)
NCT04204278ª	A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Ankle Joint	25	Mar 2021 (completed)
NCT04204083ª	A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint	25	Mar 2021 (completed)

# Table 1. Summary of Key Trials

NCT: national clinical trial

<sup>a</sup> Denotes industry-sponsored or cosponsored trial



# Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, the input does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

## 2011 Input

In response to requests, input was received from 5 academic medical centers (6 reviewers) and 3 physician specialty societies while this policy was under review in 2011. Most reviewers agreed that IA hyaluronan of the knee was medically necessary. In addition, those providing input supported an interval of 6 months for repeat injections. In response to a question about total number of treatment courses, there was no consensus.

### **Practice Guidelines and Position Statements**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American Medical Society for Sport Medicine

In 2016, the scientific statement from the American Medical Society for Sport Medicine recommended IA hyaluronan for "appropriate" patients with knee OA based on high-quality evidence.<sup>13</sup> Patient selection criteria included individuals age 60 and older with Kellgren-Lawrence grade 2 or 3 OA. The society also "suggests" IA hyaluronan for patients under age 60 with knee OA based on moderate-quality indirect evidence.

# American Academy of Orthopaedic Surgeons

In 2021, the guidelines from the American Academy of Orthopaedic Surgeons (AAOS) on treatment of osteoarthritis of the knee indicated that AAOS does not recommend routine use of intra-articular hyaluronic acid for patients with symptomatic knee osteoarthritis.<sup>49</sup> This recommendation was moderate. It was based on a meta-analysis of 28 studies that showed the overall effect was less than 0.5 minimally important different units, indicating a low likelihood that an appreciable number of patients achieved clinically important benefits. These guidelines replaced 2013 guidelines, which included a strong recommendation against use of intra-articular hyaluronic acid.

In 2023, the AAOS clinical practice guidelines on hip osteoarthritis included a recommendation that intra-articular hyaluronic acid could not be recommended in patients with symptomatic hip osteoarthritis, because it was not better than a placebo.<sup>50</sup> This was based on strong evidence as assessed in 5 high-quality studies that evaluated intra-articular hyaluronan against corticosteroids and placebo. Several studies showed no difference in patient pain and function after treatment with intra-articular hyaluronan against placebo. Studies reviewing different formulations of intra-articular hyaluronan were also considered.

In 2009 (reaffirmed in 2014), the AAOS clinical practice guidelines on glenohumeral joint OA included a weak grade C recommendation that the "use of injectable viscosupplementation is an option when treating patients with glenohumeral [shoulder] osteoarthritis."<sup>51</sup> Grade C recommendations are based on poor-quality evidence. In this instance, the recommendation was based on a single case series of 30 patients with OA of the glenohumeral joint who received 3 weekly IA injections of hylan G-F 20 (Synvisc).<sup>52</sup> At 1, 3, and 6 months, clinically significant improvements were seen in pain, function, and quality of life measures. In 2020, the updated AAOS clinical practice guidelines stated that "strong evidence supports that there is no benefit in the use of hyaluronic acid in the treatment of glenohumeral joint osteoarthritis."<sup>53</sup>

# American College of Rheumatology

In 2019, the American College of Rheumatology updated its guidelines on OA of the hand, hip, and knee.<sup>54</sup> A conditional recommendation against the use of intra-articular hyaluronic acid was given for the treatment of OA of the knee and first carpometacarpal joint of the hand. The College also made a strong recommendation against the use of intra-articular hyaluronic acid for the treatment of osteoarthritis of the hip. These recommendations were informed by a



review indicating that the effect size of hyaluronic acid injections compared to saline injections approaches 0 when analysis is limited to trials with low risk of bias. While the evidence of lack of benefit is higher quality for the hip, the conditional recommendation for osteoarthritis of the knee and hand was made in the context of clinical shared decision-making that recognizes the treatment may provide benefit when alternatives have failed to provide benefit and have been exhausted.

### **Osteoarthritis Research Society International**

In 2014, the Osteoarthritis Research Society International (OARSI) guidelines, developed by consensus after review of existing guidelines and systematic reviews, gave an "uncertain" recommendation for the use of IA hyaluronan for knee OA and a recommendation of "not appropriate" for multi-joint OA.<sup>55</sup>

In 2019, OARSI updated these guidelines, as derived from expert consensus and review of highquality meta-analytic data. Intra-articular hyaluronic acid was conditionally recommended for the treatment of knee osteoarthritis for longer term treatment effect, as it was associated with symptom improvement beyond 12 weeks with a favorable safety profile. This recommendation was provided with high consensus for patients with comorbidities (e.g., gastrointestinal, cardiovascular, frailty). This recommendation was provided with low consensus for patients with no comorbidities. The use of hyaluronic acid for the treatment of hip or polyarticular osteoarthritis was not recommended.<sup>56</sup>

# National Institute for Health and Clinical Excellence

In 2022, the clinical guideline issued by the National Institute for Health and Care Excellence for osteoarthritis diagnosis and management stated: "Do not offer intra-articular hyaluronan injections to manage osteoarthritis."<sup>57</sup>

### Medicare National Coverage

There is no national coverage determination.

### **Regulatory Status**

Several preparations of intra-articular (IA)hyaluronan have been approved by the US Food and Drug Administration (FDA) as an alternative to nonsteroidal anti-inflammatory drug therapy in the treatment of OA of the knee:

- Synvisc and Synvisc-One (Sanofi)
- GenVisc 850 (OrthogenRX)
- Gel-One (Zimmer Biomet)
- Hyalgan (Fidia Pharma)
- Supartz FX (Bioventus)
- Orthovisc (Anika)
- Euflexxa, previously named Nuflexxa (Ferring)
- Monovisc (Anika Therapeutics)
- Durolane (Bioventus)
- GELSYN-3 (Bioventus )
- Synooynt (Arthrex)
- Hymovis (Fidia Pharma)
- TriVisc (OrthogenRX)
- Visco-3 (Zimmer Biomet)
- Triluron (Fidia Pharma)

Most products are manufactured from rooster combs, except for Durolane, Euflexxa, Orthovisc, Monovisc, Gel-Syn, Hymovis, TriVisc, and GenVisc 850, which are produced from bacterial fermentation. Also, Synvisc and other products undergo additional chemical crosslinking to create hylans with increased molecular weight (6000 kDa) compared with Hyalgan (500-730 kDa) and Supartz (620-1170 kDa). Monovisc is also cross-linked with a proprietary cross-linker. The differing molecular weights of the products lead to different half-lives; the half-life of Hyalgan or Supartz is estimated at 24 hours, while the half-life of Synvisc may range up to several days.



According to manufacturers' prescribing information for Synvisc and Euflexxa, IA hyaluronan is "indicated for the treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy, and to simple analgesics, e.g., acetaminophen." The product inserts further indicate that Synvisc and Euflexxa should be injected intra-articularly into the knee joint once per week for a total of 3 injections over a 2- to 3-week period. In contrast, 5 weekly injections are recommended for the Hyalgan and Supartz products, and 3 to 4 weekly injections are recommended for OrthoVisc. In 2009, the FDA approved the use of single-dose hylan G-F 20 (Synvisc-One) for the treatment of OA of the knee. In 2011, the FDA approved the use of the single-dose cross-linked hyaluronate Gel-One (also known as Gel-200) for the treatment of OA of the knee. In 2014, Monovisc was also approved as a single-dose treatment, while GELSYN-3 was approved as a course of 3 weekly injections. In 2015, GenVisc 850 was approved as a course of 3 weekly injections and Hymovis as a series of 2 injections one week apart. In 2017, Durolane was approved as a single-dose treatment and TriVisc as a course of 3 weekly injections. In 2018, Synojoynt and Visco-3 were approved as a course of 3 weekly injections. In 2019, Triluron was approved as a course of 3 weekly injections.

In 2000, the FDA approved removal of a precautionary statement from the package inserts for Hyalgan and Synvisc that stated that the safety and efficacy of repeat courses have not been established.

FDA has not approved IA hyaluronan for joints other than the knee.

FDA product code: MOZ

#### References

- 1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intra-Articular Hyaluronan Injections for Treatment of Osteoarthritis of the Knee. TEC Assessments 1998;Volume 13:Tab 17.
- 2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Intra-articular hyaluronic acid for osteoarthritis of the knee. TEC Assessments. 2014;Volume 29:Tab 6.
- 3. Samson DJ, Grant MD, Ratko TA, et al. Treatment of primary and secondary osteoarthritis of the knee (Evidence Reports/Technology Assessments No. 157). Rockville, MD: Agency for Healthcare Research and Quality; 2007.
- Agency for Healthcare Research and Quality. Evidence-based Practice Center Systematic Review Protocol: Treatment of Osteoarthritis of the Knee: An Update. 2016 July; https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/osteoarthritis-knee-update\_research-protocol.pdf. Accessed May 9, 2025.



- 5. Rutjes AW, Jüni P, da Costa BR, et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and metaanalysis. Ann Intern Med. Aug 07 2012; 157(3): 180-91. PMID 22868835
- American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee: Evidence-based guidelines. 2nd Edition. 2013; https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-theknee/osteoarthritis-of-the-knee-2nd-editiion-clinical-practice-guideline.pdf. Accessed May 9, 2025.
- 7. Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis. Osteoarthritis Cartilage. Jun 2011; 19(6): 611-9. PMID 21443958
- Colen S, van den Bekerom MP, Mulier M, et al. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. Aug 01 2012; 26(4): 257-68. PMID 22734561
- 9. Miller LE, Block JE. US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013; 6: 57-63. PMID 24027421
- 10. Johansen M, Bahrt H, Altman RD, et al. Exploring reasons for the observed inconsistent trial reports on intra-articular injections with hyaluronic acid in the treatment of osteoarthritis: Meta-regression analyses of randomized trials. Semin Arthritis Rheum. Aug 2016; 46(1): 34-48. PMID 27139169
- 11. Jevsevar D, Donnelly P, Brown GA, et al. Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review of the Evidence. J Bone Joint Surg Am. Dec 16 2015; 97(24): 2047-60. PMID 26677239
- 12. Richette P, Chevalier X, Ea HK, et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open. 2015; 1(1): e000071. PMID 26509069
- 13. Trojian TH, Concoff AL, Joy SM, et al. AMSSM scientific statement concerning viscosupplementation injections for knee osteoarthritis: importance for individual patient outcomes. Br J Sports Med. Jan 2016; 50(2): 84-92. PMID 26729890
- 14. Ammar TY, Pereira TA, Mistura SL, et al. Viscosupplementation for treating knee osteoarthrosis: review of the literature. Rev Bras Ortop. 2015; 50(5): 489-94. PMID 26535192
- 15. Strand V, McIntyre LF, Beach WR, et al. Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res. 2015; 8: 217-28. PMID 26005358
- 16. Wang F, He X. Intra-articular hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: A meta-analysis. Exp Ther Med. Feb 2015; 9(2): 493-500. PMID 25574222
- 17. Newberry SJ, Fitzgerald JD, Maglione MA, et al. Systematic Review for Effectiveness of Hyaluronic Acid in the Treatment of Severe Degenerative Joint Disease (DJD) of the Knee. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
- 18. Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. Jan 06 2015; 162(1): 46-54. PMID 25560713
- 19. O'Hanlon CE, Newberry SJ, Booth M, et al. Hyaluronic acid injection therapy for osteoarthritis of the knee: concordant efficacy and conflicting serious adverse events in two systematic reviews. Syst Rev. Nov 04 2016; 5(1): 186. PMID 27814744
- 20. Pereira TV, Jüni P, Saadat P, et al. Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ. Jul 06 2022; 378: e069722. PMID 36333100
- Migliorini F, Maffulli N, Schäfer L, et al. Less Pain with Intra-Articular Hyaluronic Acid Injections for Knee Osteoarthritis Compared to Placebo: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Pharmaceuticals (Basel). Nov 20 2024; 17(11). PMID 39598466



- 22. Ran J, Yang X, Ren Z, et al. Comparison of intra-articular hyaluronic acid and methylprednisolone for pain management in knee osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg. May 2018; 53: 103-110. PMID 29574247
- Miller LE, Fredericson M, Altman RD. Hyaluronic Acid Injections or Oral Nonsteroidal Anti-inflammatory Drugs for Knee Osteoarthritis: Systematic Review and Meta-analysis of Randomized Trials. Orthop J Sports Med. Jan 2020; 8(1): 2325967119897909. PMID 32047830
- Phillips M, Vannabouathong C, Devji T, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis. Knee Surg Sports Traumatol Arthrosc. Sep 2020; 28(9): 3031-3039. PMID 31897550
- Tammachote N, Kanitnate S, Yakumpor T, et al. Intra-Articular, Single-Shot Hylan G-F 20 Hyaluronic Acid Injection Compared with Corticosteroid in Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial. J Bone Joint Surg Am. Jun 01 2016; 98(11): 885-92. PMID 27252432
- 26. Askari A, Gholami T, NaghiZadeh MM, et al. Hyaluronic acid compared with corticosteroid injections for the treatment of osteoarthritis of the knee: a randomized control trail. Springerplus. 2016; 5: 442. PMID 27104130
- Farr J, Gomoll AH, Yanke AB, et al. A Randomized Controlled Single-Blind Study Demonstrating Superiority of Amniotic Suspension Allograft Injection Over Hyaluronic Acid and Saline Control for Modification of Knee Osteoarthritis Symptoms. J Knee Surg. Nov 2019; 32(11): 1143-1154. PMID 31533151
- Hermans J, Bierma-Zeinstra SMA, Bos PK, et al. The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: a randomised controlled trial. BMC Musculoskelet Disord. May 07 2019; 20(1): 196. PMID 31064359
- 29. Petterson SC, Plancher KD. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc. Jun 2019; 27(6): 1992-2002. PMID 30159738
- 30. Paget LDA, Mokkenstorm MJ, Tol JL, et al. What Is the Efficacy of Intra-articular Injections in the Treatment of Ankle Osteoarthritis? A Systematic Review. Clin Orthop Relat Res. Sep 01 2023; 481(9): 1813-1824. PMID 37039814
- 31. Vannabouathong C, Del Fabbro G, Sales B, et al. Intra-articular Injections in the Treatment of Symptoms from Ankle Arthritis: A Systematic Review. Foot Ankle Int. Oct 2018; 39(10): 1141-1150. PMID 29909689
- 32. Witteveen AG, Hofstad CJ, Kerkhoffs GM. Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle. Cochrane Database Syst Rev. Oct 17 2015; 2015(10): CD010643. PMID 26475434
- 33. Migliore A, Giovannangeli F, Bizzi E, et al. Viscosupplementation in the management of ankle osteoarthritis: a review. Arch Orthop Trauma Surg. Jan 2011; 131(1): 139-47. PMID 20697901
- 34. Munteanu SE, Zammit GV, Menz HB, et al. Effectiveness of intra-articular hyaluronan (Synvisc, hylan G-F 20) for the treatment of first metatarsophalangeal joint osteoarthritis: a randomised placebo-controlled trial. Ann Rheum Dis. Oct 2011; 70(10): 1838-41. PMID 21791454
- 35. Kroon FP, Rubio R, Schoones JW, et al. Intra-Articular Therapies in the Treatment of Hand Osteoarthritis: A Systematic Literature Review. Drugs Aging. Feb 2016; 33(2): 119-33. PMID 26650235
- 36. Trellu S, Dadoun S, Berenbaum F, et al. Intra-articular injections in thumb osteoarthritis: A systematic review and metaanalysis of randomized controlled trials. Joint Bone Spine. Oct 2015; 82(5): 315-9. PMID 25776442
- 37. Riley N, Vella-Baldacchino M, Thurley N, et al. Injection therapy for base of thumb osteoarthritis: a systematic review and meta-analysis. BMJ Open. Sep 11 2019; 9(9): e027507. PMID 31511280





- 38. Kroon FPB, Carmona L, Schoones JW, et al. Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. RMD Open. 2018; 4(2): e000734. PMID 30402266
- 39. Lieberman JR, Engstrom SM, Solovyova O, et al. Is intra-articular hyaluronic acid effective in treating osteoarthritis of the hip joint?. J Arthroplasty. Mar 2015; 30(3): 507-11. PMID 25542833
- 40. Wu B, Li YM, Liu YC. Efficacy of intra-articular hyaluronic acid injections in hip osteoarthritis: a meta-analysis of randomized controlled trials. Oncotarget. Oct 17 2017; 8(49): 86865-86876. PMID 29156841
- 41. Zhao Z, Ma JX, Ma XL. Different Intra-articular Injections as Therapy for Hip Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy. May 2020; 36(5): 1452-1464.e2. PMID 31919027
- 42. Liao YY, Lin T, Zhu HX, et al. Intra-Articular Viscosupplementation for Patients with Hip Osteoarthritis: A Meta-Analysis and Systematic Review. Med Sci Monit. Aug 27 2019; 25: 6436-6445. PMID 31454342
- 43. Gazendam A, Ekhtiari S, Bozzo A, et al. Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials. Br J Sports Med. Mar 2021; 55(5): 256-261. PMID 32829298
- 44. Colen S, Geervliet P, Haverkamp D, et al. Intra-articular infiltration therapy for patients with glenohumeral osteoarthritis: A systematic review of the literature. Int J Shoulder Surg. Oct 2014; 8(4): 114-21. PMID 25538430
- 45. Zhang B, Thayaparan A, Horner N, et al. Outcomes of hyaluronic acid injections for glenohumeral osteoarthritis: a systematic review and meta-analysis. J Shoulder Elbow Surg. Mar 2019; 28(3): 596-606. PMID 30502030
- Familiari F, Ammendolia A, Rupp MC, et al. Efficacy of intra-articular injections of hyaluronic acid in patients with glenohumeral joint osteoarthritis: A systematic review and meta-analysis. J Orthop Res. Nov 2023; 41(11): 2345-2358.
  PMID 37314198
- 47. Blaine T, Moskowitz R, Udell J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am. May 2008; 90(5): 970-9. PMID 18451387
- 48. Kwon YW, Eisenberg G, Zuckerman JD. Sodium hyaluronate for the treatment of chronic shoulder pain associated with glenohumeral osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. J Shoulder Elbow Surg. May 2013; 22(5): 584-94. PMID 23333168
- American Academy of Orthopaedic Surgeons. Management of osteoarthritis of the knee (non-arthroplasty): Evidencebased clinical practice guidelines. 3rd Edition. 2021; https://aaos.org/globalassets/quality-and-practiceresources/osteoarthritis-of-the-knee/oak3cpg.pdf. Accessed May 9, 2025.
- American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Hip Evidence-Based Clinical Practice Guideline. 2023; https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-hip/oahcpg.pdf. Accessed May 9, 2025.
- American Academy of Orthopaedic Surgeons. The treatment of glenohumeral joint osteoarthritis: guideline and evidence report. 2009; https://www.aaos.org/globalassets/quality-and-practice-resources/glenohumeral/glenohumal-jointosteoarthritis-clinical-practice-guideline-4-24-19.pdf. Accessed May 9, 2025.
- 52. Silverstein E, Leger R, Shea KP. The use of intra-articular hylan G-F 20 in the treatment of symptomatic osteoarthritis of the shoulder: a preliminary study. Am J Sports Med. Jun 2007; 35(6): 979-85. PMID 17395958
- American Academy of Orthopaedic Surgeons. Management of glenohumeral joint osteoarthritis: evidence-based clinical practice guideline. 2020; https://www.aaos.org/globalassets/quality-and-practice-resources/glenohumeral/gjocpg.pdf. Accessed May 9, 2025.



- 54. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. Feb 2020; 72(2): 220-233. PMID 31908163
- 55. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. Mar 2014; 22(3): 363-88. PMID 24462672
- 56. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. Nov 2019; 27(11): 1578-1589. PMID 31278997
- 57. National Institute for Health and Care Excellence (NICE). Osteoarthritis in over 16s: diagnosis and management [NG226]. 2022; https://www.nice.org.uk/guidance/ng226. Accessed May 9, 2025.

### History

Date	Comments
05/08/12	New policy, add to Medicine section. This policy replaces 5.01.506. Added the table listing FDA approved hyaluranon products and recommended course(s) of treatment per MPC request. The 3 <sup>rd</sup> sentence of the 4 <sup>th</sup> paragraph regarding The product inserts further indicateswas moved from the description to the policy guidelines section for ease of policy administration. Policy approved with 90-day hold for provider notification. The policy effective date is November 7, 2012.
08/03/12	Correct Error on Related Policy number. Changed from 7.01.118 to 7.01.117.
08/27/12	Update Coding Section – ICD-10 codes are now effective 10/01/2014.
11/07/12	Policy effective after hold for provider notification. 5.01.506 is deleted.
03/08/13	Policy updated. Rationale and references revised. "in the knee when the above criteria are not met, and" was added to the investigational statement.
07/16/13	Update Related Policies. Add 7.01.549, and remove 7.01.188 as it was archived.
11/11/13	Replace Policy. Policy updated with literature review through July 31, 2013; reference 7 added; policy changed to not medically necessary based on new guidelines from the American Academy of Orthopaedic Surgeons. Policy change aligns with UM initiative and recent change in coverage from BCBSA. Policy held for provider notification; the effective date is April 1, 2014.
12/09/13	Minor update: When this policy was approved last month a sentence was left out. A second policy statement is now included: "Intra-articular hyaluronan injections are considered not medically necessary to treat osteoarthritis of any joint other than the knee."
01/23/14	Policy implementation delayed; the effective date of the policy is moved to June 1, 2014.



Date	Comments
03/03/14	Policy implementation delayed; the effective date of the policy is moved to July 1, 2014.
05/09/14	Revised implementation date September 1, 2014. Delayed due to Plan internal system updates.
07/24/14	Update Related Policies. Change title to 7.01.549.
08/25/14	Policy implementation delayed until December 1, 2014.
12/08/14	Interim review. Policy updated with literature review; the policy statement is unchanged. Intra-articular hyaluronan for osteoarthritis is considered not medically necessary. Effective 03/1/15.
01/05/15	Coding update. New HCPCS code J7327 added to the policy.
02/09/15	Policy implementation date extended to May 1, 2015.
03/13/15	Policy implementation date extended to June 1, 2015.
03/24/15	Update Related Policies. Change title to 7.01.549.
04/14/15	Implementation update: Policy will now be effective July 1, 2015. In the interim, see policy 2.01.534 (effective 4/14/15) for coverage (link provided in header).
06/01/15	Coding update. ICD-9 codes removed; these are not utilized in policy adjudication.
12/08/15	Annual Review. Policy reviewed with literature search. No change to policy statements.
01/19/16	Coding update. New HCPCS codes J7328 and Q9980, effective 1/1/16, added to policy.
07/01/16	Annual Review, approved June 14, 2016. Policy updated with literature review through February 12, 2016; references 10-18, and 21-24 added. Policy statements unchanged. Introduction added. Background information deleted.
09/30/16	Policy moved into new format; no change to policy statements.
01/01/17	Coding update; added new HCPCS codes J7320 and J7322 effective 1/1/17.
07/01/17	Annual Review, approved June 6, 2017. Policy updated with literature review through February 23, 2017; references 5, 11, 20-22, and 29 added. Policy statements unchanged.
01/01/18	Removed HCPCS code Q9980 as it terminated on 1/1/17.
07/01/18	Annual Review, approved June 5, 2018. Policy updated with literature review through February 2018; references 29 and 33 added. Policy statements unchanged.
01/01/19	Coding update, added new HCPCS codes J7318 and J7329 (new codes effective 1/1/19)
07/01/19	Annual Review, approved June 4, 2019. Policy updated with literature review through February 2019; reference added. Policy statements unchanged.
10/01/19	Coding updated, added HCPCS J7331 and J7332 (new codes effective 10/1/19).

Date	Comments
07/01/20	Annual Review, approved June 4, 2020. Policy updated with literature review through January 2020; references added. Policy statements unchanged. HCPCS code J7333 removed.
07/02/20	Coding update. Removed HCPCS codes J7331 and J7332. Related policy 7.01.549 removed.
12/01/20	Coding update. Added HCPCS codes J7331, J7332, J7333.
04/01/21	Coding update. Added term date to HCPC J7333.
07/01/21	Annual Review, approved June 1, 2021. Policy updated with literature review through January 11, 2021; references added. Policy statements unchanged.
07/01/22	Policy renumbered from 2.01.31 Intra-Articular Hyaluronan Injections for Osteoarthritis to 2.01.534 Intra-Articular Hyaluronan Injections for Osteoarthritis, approved June 14, 2022. Policy updated with literature review through February 28, 2022; reference added. Policy statement unchanged. Removed HCPCS code J7333.
07/01/23	Annual Review, approved June 12, 2023. Policy updated with literature review through February 13, 2023; reference added. Policy statements unchanged. Changed the wording from "patient" to "individual" throughout the policy for standardization.
07/01/24	Annual Review, approved June 10, 2024. Policy updated with literature review through February 26, 2024; references added. Policy statements unchanged.
07/01/25	Annual Review, approved June 23, 2025. Policy updated with literature review through February 21, 2025; reference added. Policy statements unchanged.

**Disclaimer**: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2025 Premera All Rights Reserved.

**Scope**: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.